Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 157-163

  Lampertico, Pietro ^a   Viganò, Mauro ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic hepatitis B; HBeAg negative; HBsAg levels; HBV DNA; IL28B polymorphism; PEG IFN ; Sustained response

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TENOFOVIR; VIRUS DNA;

ANEMIA; ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HUMAN; MONOTHERAPY; NEUTROPENIA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872039847     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12064     Document Type: Review

References (35)

1. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
3. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472-89.
4. Caliceti P. Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 2004; 36: S334-9.
5. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2011; 40: 539-51.
6. Lampertico P, Del Ninno E, Viganò M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-63.
7. Oliveri F, Puoti M, Santantonio T, et al. Efficacy and impact on disease progression of IFN treatment in patients with HBeAg-negative chronic hepatitis B: a long term Italian multicenter A.I.S.F. cohort study. Hepatology 2005; 42: 577A.
8. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58.
9. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
10. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24: S17-21.
11. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-13.
12. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-70.
13. Di Marco V, Lo Iacono O, Cammà C, et al. The long term course of chronic hepatitis B. Hepatology 1999; 30: 257-64.
14. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
15. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
16. Piratvisuth T, Marcellin P, Brunetto M, et al. Sustained immune control 1 year post-treatment with Peginterferon Alfa-2a [40KD] (PEGASYS) is durable up to 5 years post-treatment and is associated with a high rate of HBsAg clearance in HBeAg-negative chronic hepatitis B. 20th Conference of the Asian Pacific Association for the Study of the Liver (APASL), 25-28 March 2010, Beijing, China.
17. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
18. Lampertico P, Viganò M, Cheroni C, et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg negative patients with chronic hepatitis B. Hepatology 2012. doi: 10.1002/hep.25749.
19. Lampertico P, Galmozzi E, Colombo M. Studies of IL28B genotype and response to peginterferon in chronic hepatitis B Should be stratified by HBV genotype. Hepatology 2012. doi: 10.1002/hep.25882. [Epub ahead of print]
20. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. Antivir Ther 2009; 14: 1165-74.
21. Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2011; 18: 580-6.
22. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762-9.
23. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis virus DNA without hepatitits B e antigen in serum. Hepatology 1997; 26: 1621-5.
24. Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102: 2718-23.
25. Lampertico P, Viganò M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2012; PMID: 22859496.
26. Marcellin P, Lau GK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28: 477-85.
27. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
28. Marcellin P, Piratvisuth T, Brunetto M, et al. On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year posttreatment, subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a. Hepatol Int 2010; 4: 151.
29. Lampertico P, Viganò M, Galeota Lanza A, et al. PegBeLiver study: HBsAg decline at week 24 of extended peginterferon alfa-2a (Peg-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype D patients. J Hepatol 2011; 54: S293.
30. Marcellin P, Brunetto M, Bonino F, et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Hepatology 2008; 48: 718A.
31. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
32. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
33. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-11.
34. Kittner JM, Sprinzl MF, Grambihler A, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012; 54: 93-5.
35. Lampertico P, Invernizzi F, Soffredini R, et al. Add-on Peg-IFN improves HBsAg kinetics in patients long-term fully suppressed by nucleos(t)ide analogs. J Hepatol 2012; 56S: S207.